HCPLive Network

Phototherapy Affects Serum 25(OH)D Levels

 
THURSDAY, Sept. 19 (HealthDay News) -- For patients with inflammatory skin conditions, phototherapy with ultraviolet (UV) A1 radiation induces a reduction in serum 25-hydroxyvitamin D3 (25[OH]D) levels, whereas narrowband UVB (UVBnb) and UVA/UVBnb induces significant increases in serum 25(OH)D, according to a study published in the October issue of the Journal of the American Academy of Dermatology.

Laurence Feldmeyer, M.D., Ph.D., from University Hospital Zurich, and colleagues examined the influence of UVA1, UVBnb, and UVA/UVBnb phototherapy on serum levels of 25(OH)D and related parameters in 116 patients with atopic dermatitis, psoriasis, morphea, and other inflammatory skin conditions. The participants underwent UVA1 (38 participants), UVA/UVBnb (30 participants), or UVBnb (48 participants) two to three times per week for 53 to 90 days.

The researchers found that, after the therapy, UVBnb phototherapy correlated with a significant increase in serum 25(OH)D, from 22.1 to 39.5 ng/mL. Upon application of UVBnb phototherapy, the increase in 25(OH)D was steeper with a lower baseline 25(OH)D. A significant increase in serum 25(OH)D was also seen with UVA/UVBnb therapy, from 23.9 to 50.3 ng/mL. In contrast, in the UVA1 therapy group there was a significant decrease in 25(OH)D serum levels, from 21.9 to 19.0 ng/mL.

"In conclusion, phototherapy has an impact on 25(OH)D levels in the serum," the authors write. "Our study data [call] for closer examination of a potential confounding effect of various skin diseases and the need for oral vitamin D supplementation in UVA1-treated patients."

The study was funded by Spirig Pharmaceuticals.

Abstract
Full Text (subscription or payment may be required) 

Copyright © 2013 HealthDay. All rights reserved.
 



Further Reading
The FDA has approved Baxter’s Rixubis [Coagulation Factor IX (Recombinant)], an intravenous prophylactic treatment intended to control and prevent bleeding episodes and assist with perioperative management for children 12 years and younger with hemophilia B.
A compound known as P7C3-S243 appears to keep axons from degenerating after a blast injury, a University of Iowa mouse study has found. “We propose that P7C3-S243 serves as a chemical scaffold upon which new drugs can be designed to treat patients with condition of axonal degradation such as occurs in traumatic brain injury or other neurodegenerative disease,” the researchers wrote
Nancy Chiaravalloti, PhD, shares how cognitive function impacts patients with progressive multiple sclerosis at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
A new set of guidelines from the American College of Physicians (ACP) advises physicians to prescribe exercises and behavioral therapy—not drugs—as first-line treatment for many patients with urinary incontinence (UI).
Using an experimental and highly sensitive test for cardiac troponin, a team of Johns Hopkins researchers found undetected signs of heart muscle damage in people with diabetes and pre-diabetes. That may suggest that hypoglycemia directly damages the heart.
As reported in the EMBO Molecular Medicine journal, researchers have discovered there are several types of dendritic cells within human skin that play a role in both the earlier and more advances stages of psoriasis.
A substantial proportion of primary care patients will use online personal health records that interact with the electronic health record, according to a study published online Sept. 8 in the Annals of Family Medicine.
More Reading